Reuters -- Cytokinetics Inc (CYTK.O) said its experimental drug for the treatment of a neurodegenerative disease received orphan drug status from U.S. health regulators, sending its shares up 5 percent in premarket trade.
Reuters -- Cytokinetics Inc (CYTK.O) said its experimental drug for the treatment of a neurodegenerative disease received orphan drug status from U.S. health regulators, sending its shares up 5 percent in premarket trade.